Nobivac Tricat Trio, Lyophilisate and Solvent for Suspension for Injection for Cats

Country: United Kingdom

Bahasa: Inggeris

Sumber: VMD (Veterinary Medicines Directorate)

Bahan aktif:

Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Boleh didapati daripada:

MSD Animal Health UK Limited

Kod ATC:

QI06AD04

INN (Nama Antarabangsa):

Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Borang farmaseutikal:

Lyophilisate and solvent for suspension for injection

Jenis preskripsi:

POM-V - Prescription Only Medicine – Veterinarian

Kumpulan terapeutik:

Cats

Kawasan terapeutik:

Live Viral Vaccine

Status kebenaran:

Authorized

Tarikh kebenaran:

2007-05-01

Ciri produk

Revised: February 2023
AN: 00706/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Tricat Trio, lyophilisate and solvent for suspension for
injection for cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (1 ml) of reconstituted vaccine contains:
ACTIVE SUBSTANCES:
Live attenuated feline calicivirus, strain F9:

10
4.6
PFU
1
;
Live attenuated feline rhinotracheitis virus, strain G2620A:

10
5.2
PFU
1
;
Live attenuated feline panleucopenia virus, strain MW-1:

10
4.3
CCID
50
2
.
1
PFU: Plaque-Forming Units
2
CCID
50
: Cell Culture Infectious Dose 50%
EXCIPIENTS:
QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS_ _
Lyophilisate:
Disodium phosphate dihydrate
Hydrolysed gelatin
Pancreatic digest of casein
Sorbitol
Solvent:
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections
Lyophilisate: off-white pellet.
Solvent: clear colourless solution.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cats.
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
Active immunisation of cats:
-
to reduce the clinical signs caused by infection with feline
calicivirus (FCV) and
feline rhinotracheitis virus (FVR),
-
to prevent the clinical signs, leucopenia and virus excretion caused
by infection
with feline panleucopenia virus (FPLV).
Onset of immunity: for FCV and FVR: 4 weeks; for FPLV: 3 weeks.
Revised: February 2023
AN: 00706/2022
Page 2 of 6
Duration of immunity for FCV and FVR: 1 year; for FPLV: 3 years.
3.3
CONTRAINDICATIONS
See section 3.7.
3.4
SPECIAL WARNINGS
Vaccinate healthy animals only.
Maternal antibodies, which may persist up to the age of 9 –12 weeks,
can have a
negative influence on the efficacy of vaccination. In the presence of
maternal
antibodies, vaccination may not completely prevent the clinical signs,
leucopenia and
virus excretion following an FPLV infection. In such cases where a
relatively high level
of maternally derived antibodies is expected, the vaccination schedule
should be
planned accordingly.
3.5
SPEC